# EDGAR Filing Document

**Accession Number:** 0000812796
**File Stem:** 0001104659-25-092512
**Filing Date:** 2025-9
**Character Count:** 2559
**Document Hash:** 77b3336a3e58acac1fd977051450579d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-092512.hdr.sgml**: 20260127

**ACCESSION NUMBER**: 0001104659-25-092512

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOLIGENIX, INC.
- **CENTRAL INDEX KEY:** 0000812796
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411505029
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 29 EMMONS DRIVE
- **STREET 2:** SUITE B-10
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 609-538-8200

**MAIL ADDRESS:**
- **STREET 1:** 29 EMMONS DRIVE
- **STREET 2:** SUITE B-10
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DOR BIOPHARMA INC
- **DATE OF NAME CHANGE:** 20020329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ENDOREX CORP
- **DATE OF NAME CHANGE:** 19960916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMMUNOTHERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19920703

**Soligenix, Inc.**

**29 Emmons Drive, Suite B-10**

**Princeton, NJ 08540**

September 23, 2025

**VIA EDGAR**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| **Re:&nbsp;&nbsp;&nbsp;&nbsp;** | **Soligenix, Inc.** <br>**Registration Statement on Form S-1** <br>**File No. 333-290413** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligenix, Inc. (the "Company"), the undersigned hereby requests that the Company's Registration Statement on Form S-1 (File No. 333-290413), as amended, be declared effective on September 25, 2025, at 5:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.

The Company hereby authorizes its counsel, Driscoll R. Ugarte of Duane Morris LLP, to orally modify or withdraw this request for acceleration. Please contact Mr. Ugarte at (561) 962-2139 with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted.

---

| | |
|:---|:---|
| Very truly yours, <br>SOLIGENIX, INC. | Very truly yours, <br>SOLIGENIX, INC. |
| By: | /s/ Christopher J. Schaber |
|  | Christopher J. Schaber, PhD<br>President and Chief Executive Officer |

---

cc: Driscoll R. Ugarte, P.A.

Duane Morris LLP

------